• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Sientra Inc.

    11/15/22 1:45:19 PM ET
    $SIEN
    Industrial Specialties
    Health Care
    Get the next $SIEN alert in real time by email
    SC 13D 1 brhc10044259_sc13d.htm SC 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. ________)*

    SIENTRA, INC.
    (Name of Issuer)

    Common stock, par value $0.01 per share
    (Title of Class of Securities)

    82621J105
    (CUSIP Number)

    Norman H. Pessin
    Brian L. Pessin
    400 E 51st St
    PH 31
    New York, New York 10022
    (917) 887-1982
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    November 9, 2022
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 82621J105
     13D
     Page 2 of 6 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Norman H. Pessin
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     

    5,670,9231

     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    5,670,923
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,670,923
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    1 Consists of 5,670,923 shares of common stock and warrants to purchase 1,315,000 shares of common stock at $0.46 per share.
     

    CUSIP No. 82621J105
     13D
     Page 3 of 6 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Brian L. Pessin
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    875,000
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    875,000
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    875,000
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.9%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No. 82621J105
     13D
     Page 4 of 6 Pages

    Item 1.
    Security and Issuer.

    This Schedule 13D relates to the common stock, $0.01 par value (the "Common Stock" or the “Shares”) of Sientra, Inc. (the "Issuer"), whose principal executive offices are located at Suite 200, 420 South Fairview Avenue, Santa Barbara, CA 93117.

    Item 2.
    Identity and Background.

    This Schedule 13D is being filed by and for Norman H. Pessin and Brian L. Pessin (each a “Reporting Person”).  Certain information with respect to each Reporting Person is set forth below:

     
    Name and Address:
    1)
    Norman H. Pessin
         
    400 E 51st St, PH 31
         
    New York, NY  10022
       
    2)
    Brian L. Pessin
         
    65 E 76th St, Apt 3DE
         
    New York, NY  10021
           
     
    Principal Occupation:
    1)
    Investor
       
    2)
    Investor
           
     
    Criminal Convictions:
    1)
    None
       
    2)
    None
           
     
    Civil Proceedings:
    1)
    None
       
    2)
    None
           
     
    Citizenship:
    1)
    United States
       
    2)
    United States

    Item 3.
    Source or Amount of Funds or Other Consideration.

    The aggregate purchase price of the 5,670,923 shares of Common Stock owned by Norman H. Pessin is approximately $1,432,232.48, including brokerage commissions.  The shares of Common Stock owned by Norman H. Pessin were acquired with personal funds.  The aggregate purchase price of the 875,000 shares of Common Stock owned by Brian L. Pessin is approximately $193,288.30, including brokerage commissions.  The shares of Common Stock owned by Brian L. Pessin were acquired with personal funds.

    Item 4.
    Purpose of Transaction.

    The Reporting Persons originally purchased the Shares based on the belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity.  Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.


    CUSIP No. 82621J105
     13D
     Page 5 of 6 Pages

    The Reporting Persons intend to review their investment in the Issuer on a continuing basis.  Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, communications with management and the Board of Directors of the Issuer, engaging in discussions with third parties about the Issuer, making proposals to the Issuer concerning changes to the capitalization or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in Item 4.

    Item 5.
    Interest in Securities of the Issuer.

    Norman H. Pessin owns 5,670,923 shares of Common Stock of the Issuer, constituting 5.6% of the outstanding shares thereof.  Brian L. Pessin owns 875,000 shares of Common Stock of the Issuer, constituting 0.9% of the outstanding shares thereof.

    Norman H. Pessin has sole voting and dispositive power with respect to the shares of Common Stock he owns directly.  Brian L. Pessin has sole voting and dispositive power with respect to the shares of Common Stock he owns directly.

    Schedule A attached hereto lists all transactions in securities of the Issuer during the past sixty days by the Reporting Persons.  Norman H. Pessin acquired 1,315,000 shares pursuant to prospectus offering dated October 21, 2022.  The prospectus offering included warrants to purchase 1,315,000 shares of common stock at 0.46 per share.  All other transactions were effected in the open market.

    No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock.

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    None.

    Item 7.
    Material to Be Filed as Exhibits.

    None.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
     
    Norman H. Pessin
       
     
    Brian L. Pessin
    November 14, 2022
     

    Attention.  Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).


    Schedule A

    Transactions in the Securities of the Issuer During the Past 60 Days

    Shares of Common
    Stock Bought
    Price Per
    Share ($)
    Date of
    Purchase
         
     
    Norman H. Pessin
     
         
    1,315,000
    .38
    10/21/20222
    400,000
    .22
    10/27/2022
    560,100
    .22
    10/28/2022
    400,000
    .26
    10/31/2022
    530,942
    .25
    11/1/2022
    626,747
    .21
    11/3/2022
    595,122
    .20
    11/4/2022
    700,000
    .19
    11/7/2022
    343,000
    .18
    11/8/2022
    200,000
    .20
    11/9/2022
         
         
     
    Brian L. Pessin
     
         
    600,000
    .22
    10/27/2022
    275,000
    .22
    10/28/2022


    2 1,315,000 shares were purchased pursuant to prospectus offering dated October 21, 2022.  Purchase included warrants to purchase up to 1,315,000 shares of common stock at exercise price of 0.46 per share.



    Get the next $SIEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SIEN

    DatePrice TargetRatingAnalyst
    4/14/2022$8.00Buy
    Lake Street
    More analyst ratings

    $SIEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sientra Inc. (Amendment)

      SC 13G/A - Sientra, Inc. (0001551693) (Subject)

      2/20/24 1:38:37 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/6/24 10:00:53 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/15/23 3:19:14 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    SEC Filings

    See more
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/16/24 4:15:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/13/24 9:00:40 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      1/29/24 6:07:11 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Sientra Announces Appointment of Alexander W. Casdin to Board of Directors

      IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023. "On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors," said Caro Van Hove, Executive Chair of Sientra. "With Kevin O'Boyle retiring from the Board after nearly a decade of exceptional

      6/20/23 8:35:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Appoints Two Medical Aesthetics Leaders to its Board of Directors

      SANTA BARBARA, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Dr. Irina Erenburg and Nori Ebersole to its Board of Directors effective July 16, 2021. "We are extremely pleased to welcome Irina and Nori to the Sientra Board," said Caroline Van Hove, Executive Chairwoman of Sientra. "Irina and Nori's deep respective experiences and competencies in building disruptive R&D engines and best-in-class organizations in Medical Aesthetics will significantly contribute to Sientra's high-growth strategy and our singular focus to be the number one

      7/19/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Announces Appointment of Chief Financial Officer

      SANTA BARBARA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Andy Schmidt has been appointed Chief Financial Officer (CFO) effective immediately. As a key member of Sientra's executive leadership team, Mr. Schmidt will lead the Company's financial operations. "We are extremely pleased to welcome a strong leader like Andy to the Sientra team. His experience with growth-oriented public companies will be invaluable as we work towards expanding our market share and advancing the art of plastic surgery," said Ron Menezes, President and Chief Executive Of

      7/12/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Sientra with a new price target

      Lake Street initiated coverage of Sientra with a rating of Buy and set a new price target of $8.00

      4/14/22 9:15:44 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Canaccord Genuity reiterated coverage on Sientra with a new price target

      Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $10.00 from $9.00 previously

      5/12/21 11:21:33 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SVB Leerink reiterated coverage on Sientra with a new price target

      SVB Leerink reiterated coverage of Sientra with a rating of Outperform and set a new price target of $11.00 from $10.00 previously

      5/12/21 7:20:27 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction

      Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra's BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. ("Sientra" or the "Company") announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC ("Tiger") has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business. As consideration for the acquisition, Tiger will pay a cash consid

      4/2/24 6:30:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

      IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. The Company seeks to execute an expedited sale process. Sientra will utilize existing cash reserves and $22.5 million in new money d

      2/13/24 8:30:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Financials

    Live finance-specific insights

    See more
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook

      IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million in the prior year period. Third quarter results were adversely affected by overall softness in the market as well as more pronounced seasonal headwinds that led to a reduced number of augmentation and reconstru

      10/30/23 5:00:51 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Record Second Quarter Financial and Operational Results

      Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter tha

      8/10/23 4:03:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Menezes Ronald covered exercise/tax liability with 3,625 shares, decreasing direct ownership by 18% to 16,775 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:38 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Van Hove Caroline F. covered exercise/tax liability with 741 shares, decreasing direct ownership by 8% to 8,239 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:11 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form 4: Bennett Oliver Christian was granted 2,739 shares, increasing direct ownership by 13% to 23,100 units

      4 - Sientra, Inc. (0001551693) (Issuer)

      9/11/23 9:05:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care